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Abstracts / International Journal of Surgery 23 (2015) S15eS134 S31from surgical histology. 35 patients were excluded as they did not undergo
sentinel lymph node biopsy or axillary clearance.
Results: Analysis of the remaining 96 patients revealed strong negative
correlation (r ¼ 0.908) between increasing tumour size (T1 to T3) and
rate of axillary metastasis. 40% of all tumour T4 staged patients had
axillary involvement. Regardless of tumour size, South Asians had highest
tendency for axillary disease (42%) then followed by Afro-Caribbeans
(39%).
Conclusion: Based on our study, increasing primary tumour size is ironi-
cally associated with reduced rates of axillary disease. Chest wall and
cutaneous invasion strongly predict axillary metastasis. Ethnicity does
appear to alter the risk of lymphatic spread. However, further work with a
larger study population are needed for ﬁrm conclusions to be drawn.
0827: USE OF ONCOTYPE DX ASSAY REDUCES CHEMOTHERAPY IN
BREAST CANCER
T. Kiernan*, U. Sridharan, G. Mitchell. Royal Liverpool University Hospital,
UK
Aim: The future of breast cancer adjuvant treatment lies in molecular
proﬁling of tumours to determine their prognosis and sensitivity to
chemotherapy. Oncotype Dx is a 21 gene assay recommended for use by
NICE to guide adjuvant chemotherapy decisions for people with Oestrogen
Receptor positive (ER+), Lymph Node negative (LN-), Human Epidermal
growth factor Receptor 2 negative (HER2-) early breast cancer at inter-
mediate risk. Our aim is to audit the use of Oncotype Dx assay in the Royal
Liverpool University Hospital and to compare the assay score with tradi-
tional prognostic tools such as Nottingham Prognostic Index (NPI), Adju-
vant! Online and Predict.
Methods: Patients records, identiﬁed through Genomic database,
were searched for histology, demographics and adjuvant treatment
decision.
Results: 38 patients were identiﬁed, median age 59 (43e75); 16 were LN+.
76% did NOT receive chemotherapy following the assay; this represents a
40% reduction in expected use. There was no correlation of Oncotype Dx
score with the traditional prognostic tools.
Conclusion: Oncotype Dx assay should be used in all patients, including
LN+, considered for chemotherapy. Tumour histology does not necessarily
reﬂect molecular proﬁle, chemosensitivity and patient outcomes.0847: THE MANAGEMENT OF BREAST CANCER IN PATIENTS WITH
BREAST AUGMENTATION
L. Ballance a,*, D. Doherty b, A. Hamad a. aMid Cheshire Hospitals NHS
Foundation Trust, UK; bUniversity of Manchester, UK
Aim: Achieving balance between oncological and cosmetic outcomes in
Breast Cancer patients with breast augmentation (BA) is challenging. With
increasing age of womenwith BA, the management of Breast Cancer in this
cohort is likely to come under increased focus. Breast conserving surgery
(BCS) is less likely as it requires radiotherapy, with poor aesthetic out-
comes. There is a lack of clear guidance for this cohort with a call for
recommendations.
Methods: A literature review was carried out using PubMed and OVID
using key words and phrases: “breast cancer management”, “breast cancer
treatment”, “augmentation” and “previously augmented”. Papers pub-
lished since the year 2000 were considered.
Results: Fourteen papers were identiﬁed. BCS feasibility in Breast
Cancer patients with BA is low and mastectomy rates are high. BCS does
not compromise oncology outcomes but interferes with aesthetics.
Better cosmetic outcomes are seen with careful planning, patient se-
lection, novel reconstructive techniques and in those with sub-pectoral
implants.
Conclusion: There is no guidance for the management of Breast Cancer in
women with BA. BCS is a viable treatment option in these patients.
Treatment should be based on clinical judgement, patient preference and
preoperative counselling. Targeted radiation with novel reconstructive
methods may exclude aesthetic problems.0863: AXILLARY DISSECTION FOR BREAST CANCER MICROMETASTASES
TO THE SENTINEL NODE: OVERTREATMENT OR A NECESSARY EVIL?
M. Shastri*, W. Sotheran, T. Umar, L. Gould. St Richards Hospital, UK
Aim: The beneﬁts of sentinel lymph node (SN) biopsy for axillary staging
in breast cancer are well documented, although there is little consensus
regarding the subsequent management of micro and macro-metastatic
disease. We currently perform level I/II axillary dissection (AD) for SN
micrometastases in patients undergoing mastectomy, as not all receive
subsequent radiotherapy.
In this retrospective case series, we aim to determine whether there is any
beneﬁt in performing AD in mastectomy patients with micrometastases to
the SN.
Methods: We analysed histopathology reports of all patients who un-
derwent mastectomy and had micrometastases to one or more SN on One
Step Nucleic acid Ampliﬁcation (OSNA), during the 12 month period to
November 2014.
Results: 15 female patients were identiﬁed with a mean age of 59.1 years
(range 42e81 years). Most (n¼14) had invasive ductal or lobular carcinoma
+/ carcinoma in situ. Non SN involvement was present in 3 patients
however this did not result in upstaging of cancer in any case.
Conclusion: Within our cohort, AD for micrometastases to the SN in
mastectomy patients did not alter the pathological stage of cancer. We
therefore recommend AD is avoided as it does not alter patient manage-
ment and causes signiﬁcant morbidity.
0879: AUDIT OF THEATRE UTILISATION IN BREAST AND ENDOCRINE
SURGERY IN WISHAW GENERAL HOSPITAL
J. McAllister*, J. Murray. Wishaw General Hospital, UK
Aim: To determine the amount of time spent between cases and propor-
tion of theatre time spent operating in an elective breast and endocrine
practice.
Methods: The ORMIS theatre database was used to collect and analyse
timeswhenpatients entered and left theatre, andwhen surgery started and
ﬁnished. 33 operating lists performed by three surgeons were included,
comprising 146 cases over a 4-month period (January to May 2014).
Results: Of a potential 8-hour operating session (9-5), the average list
durationwas 6 hours 34minutes (including breaks). This meant an average
94% of potential available theatre time was utilised. Amongst this, 62% was
spent operating, 24%was spent prior to surgery starting, and 14%was spent
after surgery between cases. In total an average of 4 hrs 4 minutes were
spent operating (51% of potential theatre time spent operating). No signif-
icant difference was found between operating surgeon or anaesthetist.
Conclusion: Only half of the potential time available in theatre is spent
operating. While some of the other time is spent anaesthetising patients,
there is also a considerable amount of time spent with the transfer of
patients into and out of theatre.
0892: HAS THE USE OF IN-THEATRE INTRA-OPERATIVE SPECIMEN X-
RAY REDUCED OUR RE-OPERATION RATES IN BREAST CONSERVING
SURGERY?
E. Blower*, E. Redmond, J. Seward, C. Harding-Mackean. Countess of
Chester Hospital, UK
Aim: Negative margins at ﬁrst operation for breast conserving surgery
(BCS) reduce local recurrence, improve long-term breast conservation and
cosmesis. Gold-standard intra-operative conﬁrmation is departmental x-
ray. Recently, in-theatre assessment (Faxitron) may be alternatively used
allowing immediate assessment of tumour-margins. It may reduce re-
operation rates, anaesthesic time and cost. This audit aims to determine if
re-operation rates decreased and breast conservation rates increased
following Faxitron introduction.
Methods: A retrospective case-note review of consecutive patients un-
dergoing wide local excisions (WLE) both before and after Faxitron
introduction was performed. All image-guided specimens also underwent
standard departmental X-ray.
